
Himalaya Nutravedics India IPO
- Issue price
- ₹106
- Listing price
- ₹118
- +11.32%
- Current price
- ₹169.85
- +60.24%
- Subscribed
- 2.24x
- Issue size
- ₹26.5 Cr
- Listed on
- 29 Sep 2026
IPO timeline
- Opens22 SepTue
- Closes24 SepThu
- Allotment25 SepFri
- Refunds28 SepMon
- Demat credit28 SepMon
- Listing29 SepTue
Issue details
- Price band
- ₹100 – ₹106 per share
- Issue size
- ₹26.5 Cr
- Fresh issue
- ₹26.5 Cr · 0.25 Cr shares
- Offer for sale
- None
- Issue type
- Fresh capital only
- Face value
- ₹10 per share
- Lot size
- 1,200 shares
- Minimum investment
- ₹1,27,200
- Listing on
- BSE SME
- Exchange code
- HNIL.BO · 7983
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹1,27,200 |
| Retail (Max) | 1 | 1,200 | ₹1,27,200 |
| HNI (Min) | 2 | 2,400 | ₹2,54,400 |
Reservation
- QIB
- 11,84,400 shares (49.90% of the Offer)
- NII
- 3,56,400 shares (15.02% of the Offer)
- Retail
- 8,32,800 shares (35.09% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 25 Sep 2026
- Refunds initiated
- 28 Sep 2026
- Shares credited to demat
- 28 Sep 2026
- Listing
- 29 Sep 2026
Grey market premium (GMP)
- Current GMP
- ₹0
- 0.00%
- Estimated listing price
- ₹106
- Issue price ₹106
- Highest
- ₹0
- 19 Sep
- Lowest
- ₹0
- 19 Sep
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 29 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 28 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 27 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 26 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 25 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 24 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 23 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 22 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 21 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 20 Sep 2026 | ₹0 | 0.00% | ₹106 |
| 19 Sep 2026 | ₹0 | 0.00% | ₹106 |
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB1x
- NII (HNI)2.9x
- Retail2.56x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 4,74,000 | 4,74,000 | 1x |
| Non-Institutional Investors (NII) | 4,82,400 | 14,00,400 | 2.9x |
| bNII — bids above ₹10 Lakh | 2,37,600 | 10,39,200 | 4.37x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 1,18,800 | 3,61,200 | 3.04x |
| Retail Individual Investors (RII) | 8,32,800 | 21,33,600 | 2.56x |
| Total | 17,89,200 | 40,08,000 | 2.24x |
Financials
- P/E (pre-issue)
- 9.05
- P/E (post-issue)
- 12.63
- EPS (₹)
- 8.39
- RoE
- 63.87%
- RoCE
- 36.41%
- RoNW
- 45.12%
- PAT Margin
- 17.16%
- EBITDA Margin
- 18.82%
- Debt / Equity
- 0.31
- NAV (₹)
- 26.70
Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price on profit for the FY ended 31 Mar 2026.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 24.42 | 10.82 | 6.09 |
| Total Income | 43.12 | 21.00 | 14.43 |
| Profit After Tax | 7.39 | 2.23 | 0.43 |
| EBITDA | 8.10 | 2.99 | 0.94 |
| NET Worth | 16.38 | 6.75 | 1.34 |
| Reserves and Surplus | 10.07 | 2.76 | 0.53 |
| Total Borrowing | 5.13 | 1.76 | 3.24 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Himalaya Nutravedics India This IPO | ₹26.5 Cr | 12.63 | 45.12% | 17.16% | 2.24x | +11.32% |
| Speciality Medicines SME · listed 30 Mar 2026 | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
| Avience Biomedicals SME · listed 25 Jun 2026 | ₹30.24 Cr | 16.56 | 49.89% | 15.86% | 385.4x | +90.00% |
| ABH Healthcare SME · listed 1 Sep 2026 | ₹34.98 Cr | 20.69 | 39.07% | 10.74% | 1.42x | -2.94% |
| Bio Medica Laboratories SME · listed 29 May 2026 | ₹52 Cr | 13.45 | 99.59% | 25.64% | 2.31x | -20.00% |
| Goldline Pharmaceutical SME · listed 19 May 2026 | ₹12 Cr | 13.93 | 27.37% | 10.09% | 781.85x | +38.95% |
| Pramodini Medicare SME · listed 19 Aug 2026 | ₹69.04 Cr | 14.97 | 32.69% | 27.90% | 3.66x | +1.69% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Himalaya Nutravedics India plans to use the money raised, as stated in the offer document.
- Funding Working Capital Requirements₹13.75 Cr
- Business Development and Digital Marketing Activities₹7.5 Cr
- General Corporate Purposes
About Himalaya Nutravedics India
Himalaya Nutravedics India Limited was started in June 2022. It is a Hyderabad based company that formulates, manufactures and markets Ayurvedic and nutraceutical products. Its products come in several forms, including softgel capsules, tablets, medicated oils, liquid orals, hardgel capsules and protein powders. Being able to make all of these in one place is unusual for a company of this size, because each dosage form needs its own line and approvals. Its products cover therapeutic areas such as digestive health, immunity, metabolic health and pain management. It sells in two ways. Its own branded products are marketed through healthcare practitioners rather than through mass advertising, so doctors recommending the product is what drives sales. Alongside that it manufactures on a third party contract basis for other brands. It has expanded to 17 states and one union territory in India. Its manufacturing facility is in Hyderabad, Telangana and holds ISO 22000:2018, ISO 9001:2015 and WHO-GMP certification. As on 30 April 2026 it had 80 employees.
Strengths
- Sales have tripled in two years, from Rs 14.43 crore in FY2024 to Rs 21.00 crore in FY2025 and Rs 43.12 crore in FY2026.
- Profit has grown from Rs 0.43 crore in FY2024 to Rs 2.23 crore in FY2025 and Rs 7.39 crore in FY2026.
- The margin is high for a small manufacturer, with a PAT margin of 17.16% and an EBITDA margin of 18.82%.
- Return ratios are very strong, with RoNW of 45.12% and RoCE of 36.41%.
- Debt is low. Total borrowing was Rs 5.13 crore against a net worth of Rs 16.38 crore, a debt to equity ratio of only 0.31.
- The issue is priced at about 12.63 times earnings on an EPS of Rs 8.39.
- It can make several dosage forms in one facility, from softgels and tablets to oils, liquids and powders, which lets it serve a wider set of contract manufacturing customers.
- The Hyderabad facility holds WHO-GMP certification along with ISO 22000:2018 and ISO 9001:2015, which matters for both export and contract work.
Risks
- The company is very young. It was started only in June 2022, so it has around four years of history and has not been tested through a difficult period.
- The growth is from a very small base. Sales tripled and profit rose about seventeen times in two years, which cannot be assumed to continue.
- Rs 7.50 crore of the Rs 26.5 crore issue goes into business development and digital marketing. That is a running cost rather than an asset, and it will need to be spent again.
- Sales depend on healthcare practitioners recommending the products. That relationship has to be maintained continuously and can be won away by competitors.
- The whole business runs from one facility in Hyderabad, so there is single location risk.
- Ayurvedic and nutraceutical products are a crowded category with low barriers to entry and many small manufacturers.
- The contract manufacturing part of the business earns a lower margin than selling its own brands.
- Promoter holding will come down from 95.14% to 68.13% after the issue.
- This is an SME issue. One lot is 1,200 shares, which is about Rs 1.27 lakh at the upper band of Rs 106, and SME shares usually trade in low volume after listing.
Promoters and shareholding
Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsas
- Promoter holding, pre-issue
- 95.14%
- Promoter holding, post-issue
- 68.13%
Registrar, lead managers and documents
Lead manager
Company contact
Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad, Telangana, 500051
+91-9063498493
info@himalayanutravedics.comDocuments
Himalaya Nutravedics India IPO: common questions
1.When does the Himalaya Nutravedics India IPO open and close?
The Himalaya Nutravedics India IPO opens on 22 Sep 2026 and closes on 24 Sep 2026.
2.What is the price band of the Himalaya Nutravedics India IPO?
The price band is ₹100 – ₹106 per share, with a lot size of 1,200 shares and a minimum investment of ₹1,27,200.
3.What is the size of the Himalaya Nutravedics India IPO?
The issue size is ₹26.5 Cr (Fresh capital only).
4.What is the GMP of the Himalaya Nutravedics India IPO?
The last reported grey market premium is ₹0 per share as of 29 Sep 2026, 08:24 AM IST. GMP is unofficial and changes frequently.
5.When is the Himalaya Nutravedics India IPO allotment?
The basis of allotment is expected on 25 Sep 2026. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Himalaya Nutravedics India IPO list?
The shares listed on 29 Sep 2026 on BSE SME.
7.Who is the lead manager of the Himalaya Nutravedics India IPO?
The book running lead manager is Nirbhay Capital Services, and the registrar is KFin Technologies Limited.
8.What will the money raised in the Himalaya Nutravedics India IPO be used for?
As stated in the offer document, the proceeds are for: Funding Working Capital Requirements; Business Development and Digital Marketing Activities; General Corporate Purposes.
9.How can my company launch an IPO like Himalaya Nutravedics India?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393